Peer-reviewed veterinary case report
Best first-line treatments for advanced liver cancer in adults
By Luo J et al.·2026·Department of Pharmacy, China·View original on Europe PMC →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Exploring the optimal regimen in advanced hepatocellular carcinoma: a protocol of individual patient data network meta-analysis of randomized controlled trials.
Plain-English summary
This study is looking at how to best treat advanced liver cancer, known as hepatocellular carcinoma (HCC). Since a drug called sorafenib was approved in 2007, more treatment options have become available, but this can make it harder for doctors to decide which is best for each patient. The researchers will review various studies to compare these treatments based on how long patients live, any serious side effects, and other important factors. They hope their findings will help doctors make better treatment choices for patients with advanced HCC. The outcome of this research is expected to improve clinical guidelines and support personalized treatment decisions.
Abstract
<h4>Background</h4>Advanced hepatocellular carcinoma (HCC) poses a substantial global disease burden. Since the approval of sorafenib in 2007, an increasing number of treatment regimens have demonstrated encouraging survival benefits in first-line treatment of advanced HCC. However, this expansion of therapeutic options has also introduced complexity into clinical decision-making. This study aims to provide high-quality evidence to inform clinical practice by comparing all first-line treatment regimens for advanced HCC.<h4>Methods</h4>We will systematically search PubMed, Embase (Ovid), and the Cochrane Library (Ovid) from January 1, 2007, to March 3, 2026. Supplementary searches will be performed in clinical trial platforms and conference abstracts. All randomized controlled trials (RCTs) and high-quality observational studies (for prior information only) comparing active first-line treatment regimen for advanced HCC will be included. Primary outcomes are overall survival, grade ≥3 serious adverse events, and the incremental safety-effectiveness ratio. Secondary outcomes include progression-free survival, objective response rate, the incidence of all adverse events and treatment discontinuation due to adverse events. The risk of bias of included RCTs will be assessed using the Risk of Bias 2.0 tool, and the certainty of evidence for each outcome will be evaluated with the Confidence in Network Meta-Analysis (CINeMA) application. Study selection, data extraction, and quality assessment will be performed independently by two reviewers, with any disagreements adjudicated by a third reviewer. Individual patient data will be reconstructed from published Kaplan-Meier curves, and treatment effects will be evaluated using restricted mean survival time. Subgroup analyses will be performed based on PD-L1 expression, etiology, Barcelona Clinic Liver Cancer stage, alpha-fetoprotein concentration, macrovascular invasion, and extrahepatic spread. Bayesian network meta-analysis will be performed using R with the gemtc package.<h4>Discussion</h4>Our study is expected to inform clinical guidelines and support personalized therapeutic decisions for advanced HCC.<h4>Clinical trial registration</h4>https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420251126975.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Europe PMC: https://europepmc.org/article/MED/41988192